Min Weijie, Dai Dongwei, Wang Jiaqi, Zhang Dandan, Zhang Yuhui, Han Guosheng, Zhang Lei, Chen Chao, Li Xiulong, Li Yanan, Yue Zhijian
Department of Neurosurgery, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Clinical Research Center, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
PLoS One. 2016 Sep 27;11(9):e0160451. doi: 10.1371/journal.pone.0160451. eCollection 2016.
Glioma remains a diagnostic challenge because of its variable clinical presentation and a lack of reliable screening tools. Long noncoding RNAs (lncRNAs) regulate gene function in a wide range of pathophysiological processes and are therefore emerging biomarkers for prostate cancer, hepatic cancer, and other tumor diseases. However, the effective use of lncRNAs as biomarkers for the diagnosis of glioma remains unproven.
This study included 42 glioma patients and 10 healthy controls. lncRNA and mRNA microarray chips were used to identify dysregulated lncRNAs in tumor tissue and tumor-adjacent normal tissue, and SYBR Green-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate upregulated lncRNAs. A receiver operating characteristic curve analysis was conducted to evaluate the diagnostic accuracy of the lncRNA identified as the candidate biomarker.
miR210HG levels were significantly higher in tumor tissue than in tumor-adjacent normal tissue in participating glioma patients. Serum miR210HG levels were also significantly higher in glioma patients than in healthy controls. The receiver operating characteristic curve showed that serum miR210HG was a specific diagnostic predictor of acute pulmonary embolism with an area under the curve of 0.8323 (95% confidence interval, 0.7347 to 0.9299, p < 0.001).
Our findings indicate that miR210HG could be an important biomarker for the diagnosis of glioma, and, as such, large-scale investigations are urgently needed to pave the way from basic research to clinical use.
由于胶质瘤临床表现多样且缺乏可靠的筛查工具，其诊断仍具有挑战性。长链非编码RNA（lncRNA）在广泛的病理生理过程中调节基因功能，因此正成为前列腺癌、肝癌和其他肿瘤疾病的生物标志物。然而，lncRNA作为胶质瘤诊断生物标志物的有效应用仍未得到证实。
本研究纳入42例胶质瘤患者和10名健康对照。使用lncRNA和mRNA微阵列芯片鉴定肿瘤组织和肿瘤旁正常组织中失调的lncRNA，并使用基于SYBR Green的miRNA定量实时逆转录聚合酶链反应验证上调的lncRNA。进行受试者工作特征曲线分析以评估鉴定为候选生物标志物的lncRNA的诊断准确性。
在参与研究的胶质瘤患者中，肿瘤组织中的miR210HG水平显著高于肿瘤旁正常组织。胶质瘤患者血清中的miR210HG水平也显著高于健康对照。受试者工作特征曲线显示，血清miR210HG是急性肺栓塞的特异性诊断预测指标，曲线下面积为0.8323（95%置信区间，0.7347至0.9299，p<0.001）。
我们的研究结果表明，miR210HG可能是胶质瘤诊断的重要生物标志物，因此，迫切需要进行大规模研究，为从基础研究到临床应用铺平道路。
